Dan Jamieson

Dan Jamieson, Founder and CEO of Biorelate, shares insights on leveraging AI for drug discovery. He discusses how his PhD led to a partnership with Pfizer, boosting their target proposal success. Jamieson explains the significance of connecting disparate research to unveil new hypotheses and the evolution of Biorelate’s services into a scalable licensing model. He emphasizes the crucial role of domain expertise in tackling complex biomedical challenges, while highlighting AI's ability to complement, not replace, human scientists in this innovative field.